Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 1;21(11):3267-3277.
doi: 10.31557/APJCP.2020.21.11.3267.

Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital

Adhitya Bayu Perdana  1 , Rizky Ifandriani Putri  2 , Rachmawati Rachmawati  3 , Bob Andinata  4 , Bayu Brahma  4
Affiliations

Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital

Adhitya Bayu Perdana et al. Asian Pac J Cancer Prev. .

Abstract

Molecular testing of thyroid nodules becomes important for improving the accuracy of fine-needle aspiration biopsy (FNAB). This study aimed to investigate the diagnostic utility of BRAF, NRAS, and TERT promoter mutation in thyroid nodules at Dharmais Cancer Hospital.<br />Methods: We performed a prospective diagnostic study involving 50 patients with thyroid nodules who needed surgery between September 2013 and August 2014. Mutational hotspots in BRAF exon 15, NRAS exon 3, and TERT promoter region were analyzed by Sanger sequencing from FNAB specimens. Cytology and molecular data were compared to histopathology results.<br />Result: Of the 50 cases included in the analysis, 39 cases (78%) were thyroid malignancies. Mutations of BRAF, NRAS, and TERT promoter were detected in 31% (12/39), 18% (7/39), and 13% (5/39) cases, respectively. BRAF and NRAS mutations were found mutually exclusive, while all of TERT promoter mutation was found coexistent either with BRAF (40%) or NRAS (60%). The combination of FNAB cytology and molecular testing resulted in 69% sensitivity, 100% specificity, 100% positive predictive value, 48% negative predictive value, and 76% accuracy.<br />Conclusion: Molecular testing of BRAF, NRAS, and TERT mutations improve the sensitivity of thyroid FNAB and is beneficial for more definitive treatment in selective cases. However, the NPV is relatively low to avoid the need for diagnostic surgery. Therefore, further studies to identify more sensitive methods and more comprehensive molecular markers in the diagnosis of thyroid nodules are needed.

Keywords: Diagnostic; Thyroid cancer; fine-needle aspiration biopsy; hotspot mutation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients Inclusion Flowchart for Mutation Analysis
Figure 2
Figure 2
Representative Sequencing Results for BRAF, NRAS, and TERT Promoter Mutation. (A) Sequence of wildtype BRAF exon 15, codon 600 (GTG, arrow). (B) Sequence of mutant BRAF exon 15, codon 600, showing overlapping peak (GTG>GAG, arrow) indicated substitution of amino acid valine to glutamic acid. (C) Sequence of wildtype NRAS exon 3, codon 61 (CAA, arrow). (D) Sequence of mutant NRAS exon 3, codon 61, showing overlapping peak (CAA>CGA, arrow) indicated substitution of amino acid glutamine to arginine. (E) Sequence of wildtype TERT promoter (CTCCGG, arrow). (F) Sequence of mutant TERT promoter, showing overlapping peak at nucleotide base position number 1,295,228 (228C>T, arrow)
Figure 3
Figure 3
Mutation Status of FNAB Specimens. The thyroid nodules are categorized based on cytology results as malignant, indeterminate, and benign. *FNAB, fine needle aspiration biopsy; AC, anaplastic carcinoma; PDTC, poorly differentiated thyroid carcinoma; PTCcv, papillary thyroid carcinoma classic variant; PTCfv, papillary thyroid carcinoma follicular variant
See this image and copyright information in PMC

References

    1. Albarel F, Conte-Devolx B, Oliver C. From nodule to differentiated thyroid carcinoma: Contributions of molecular analysis in 2012. Ann Endocrinol. 2012;73:155–64. - PubMed
    1. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705–15. - PubMed
    1. Argyropoulou M, Veskoukis AS, Karanatsiou PM, et al. Low prevalence of TERT Promoter, BRAF and RAS mutations in papillary thyroid cancer in the Greek population. Pathol Oncol Res. 2020;26:347–54. - PubMed
    1. Auger M, Nayar R, Khalbuss W, et al. Implementation of the bethesda system for reporting thyroid cytopathology. Arch Pathol Lab Med. 2013;137:1555–9. - PubMed
    1. Bae JS, Choi SK, Jeon S, et al. Impact of NRAS mutations on the diagnosis of follicular neoplasm of the thyroid. Int J Endocrinol. 2014;2014:1–7. - PMC - PubMed

MeSH terms